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NICE guidance on dapagliflozin for type 1 diabetes 
 
 
On August 28, 2019, the National Institute for Health and Care Excellence (NICE) published 
guidance recommending dapagliflozin (a sodium-glucose co-transporter-2 inhibitor) for 
treating type 1 diabetes in adults with a BMI of at least 27 kg/m2 when insulin alone does not 
provide adequate glycaemic control despite optimal insulin therapy.1  However, the guidance 
applies only if patients are on insulin doses of more than 0.5 units per kg body weight per 
day; they have completed a structured education programme that includes information about 
diabetic ketoacidosis (DKA) such as recognising its risk factors, signs, and symptoms, how 
and when to monitor blood ketones, and what actions to take; and, treatment is started and 
supervised by a consultant physician specialising in endocrinology and diabetes. The 
structured education course, in line with the NICE Quality Standard for diabetes2 should be 
evidence based and quality-assured, and be delivered by trained educators. 
 
The NICE appraisal focused on the newer indication of type 1 diabetes. AstraZeneca 
(Cambridge, UK) submitted clinical and cost-effectiveness evidence, which an independent 
appraisal committee considered during two public meetings; clinical and patient experts 
attended the first meeting. 
 
The committee was aware that the European Medicines Agency had limited the dapagliflozin 
license because of safety concerns about DKA to people with a BMI of at least 27 kg/m, 
adequate education about DKA, and without low insulin needs.  It also limited the license to 
a glomerular filtration rate t60 mL/min per 1.73 m2 when starting treatment. The committee 
took advice on how to define low insulin needs from the clinical experts and concluded that it 
was appropriate to evaluate dapagliflozin in people in whom, despite structured education, 
insulin alone did not control blood glucose; the comparator, therefore, was optimised 
treatment with insulin. 
 
As evidence of clinical effectiveness, AstraZeneca presented data from the DEPICT-13 [and 
DEPICT-24 randomised trials, which compared dapagliflozin plus insulin therapy at 5 mg 
[licensed] or 10 mg [unlicensed] doses with placebo plus insulin therapy over 52 weeks in 
patients with inadequately controlled type 1 diabetes despite optimised insulin therapy and 
with HbA1c levels ranging from 7.5% (59 mmol/mol) to 10.5% (91 mmol/mol). The license, 
and the evidence presented to the committee, reflects a subset of the trial participants 
(n=561). The committee recognised that more people used continuous subcutaneous insulin 
infusion (pumps) and fewer used renin-angiotensin-aldosterone system inhibitors than NHS 
patients who might receive dapagliflozin, but considered that this was unlikely to modify 
GDSDJOLIOR]LQ¶Veffect. 
 
The primary measure of effectiveness in both trials was the change in HbA1c from baseline 
to 24 weeks, whereas 1,&(¶Vmeasure of effectiveness is the quality-adjusted life year 
(QALY).5 The DEPICT trials showed no evidence that dapagliflozin prolongs life, but showed 
a small increase in quality of life. Yet, AstraZeneca proposed that dapagliflozin plus insulin 
increases both length and quality of life compared with insulin alone over a lifetime. The 
committee noted that the pooled reduction in HbA1c at 52 weeks from the DEPICT trials was 
modest at 0.34% relative to placebo, and questioned whether it was important, and would be 
sustained. People randomized to dapagliflozin lost weight at 24 weeks, which was sustained 
at 52 weeks. The committee concluded that, in general, any decrease in HbA1c without 
substantial hypoglycaemia or weight gain is desirable. 
 
To support its case that dapagliflozin prolongs life and improves quality of life, AstraZeneca 
used a patient-level model6 to simulate disease progression and complications over a 
lifetime. The company derived risk equations linking HbA1c to future complications using the 
randomised Diabetes Control and Complications Trial (DCCT)7 and its follow-on 
observational study, the Epidemiology of Diabetes Interventions and Complications (EDIC)8 
for microvascular complications, and the Swedish National Diabetes Registry9 for 
macrovascular complications. AstraZeneca did not link changes in body weight to changes 
in the risk of complications, but did link changes to an increase in quality of life. Because 
studies in other populations to validate the model were limited, the committee concluded that 
it was uncertain how well the model predicted long-term complications following a relatively 
short observed period of modestly improved glycaemic control. 
 
The committee queried why AstraZeneca had not used DCCT/EDIC-based data to model 
cardiovascular disease. The company explained that it could not access the patient-level 
data within the consultation period and the committee acknowledged that a scenario in 
which HbA1c did not affect cardiovascular risk had not markedly changed the cost-
effectiveness results. 
 
The committee noted that nearly all modelled improvements in QALYs occurred in the 
extrapolated period after the end of the DEPICT trials, for which there was no observed 
evidence. In response, AstraZeneca provided scenarios in which it modelled varying 
degrees of treatment effect waning over time for HbA1c and for weight loss with dapagliflozin 
plus insulin. The committee appreciated that the gains in QALYs were largely from quality-
of-life gains in people who lost weight. 
 
The model presented by AstraZeneca at the second committee meeting included people 
who need more than 0.5 units of insulin per kg body weight per day; a progressive increase 
in HbA1c of 0.045% per year and in body weight of 0.1 kg per year for both arms; a stopping 
rate in year 1 and beyond for dapagliflozin based on DEPICT; and mortality and disutility 
associated with severe hypoglycaemia, DKA, and life-threatening urogenital infections, such 
DV)RXUQLHU¶VJDQJUHQH. AstraZeneca modelled scenarios using both additive and 
multiplicative approaches to apply disutilities associated with complications10 and costs 
related to increased blood glucose testing, additional ketone monitoring and visits to 
diabetes specialist teams. The committee noted that the deterministic incremental cost-
effectiveness ratio (ICER) for AstraZeneca¶VUHYLVHGEDVHFDVHZDV below the range that 
NICE considers to be cost effective; that is, below £20,000 per QALY gained. 
 
The committee noted that AstraZeneca provided two scenarios in which it modelled: first, no 
treatment effects affecting HbA1c or weight beyond the 52 week trial for either treatment and 
stopping dapagliflozin; and second, no change in HbA1c from baseline for either treatment, 
but maintaining a weight benefit and not stopping dapagliflozin. The committee 
acknowledged that both of the scenarios tested resulted in ICERs that fell within the range 
NICE normally considers to be cost effective. 
 
The committee recognised that if HbA1c did not improve, ongoing treatment with 
dapagliflozin would likely subject the patient to risks. The committee recognised that 
dapagliflozin did not have an indication for weight loss, and that the trials did not include 
VWRSSLQJµUXOHV¶. The committee concluded that if glycaemic control does not improve, it 
would not be appropriate to continue dapagliflozin. 
 
The committee concluded that dapagliflozin with insulin appears to be a cost-effective use of 
NHS resources for treating type 1 diabetes in adults with a BMI of at least 27 kg/m2 when 
insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, 
subject to the above-listed conditions. The guidance also states that people should stop 
dapagliflozin if they do not see a sustained improvement in glycaemic control when 
assessed after 6 months and regularly thereafter. 
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